Cannabis use is a heritable trait [1] that has been associated with adverse mental health outcomes.
To identify risk variants and improve our knowledge of the genetic etiology of cannabis use, we performed the largest genome-wide association study (GWAS) meta-analysis for lifetime cannabis use (N=184,765) to date. We identified 4 independent loci containing genome-wide significant SNP associations. Gene-based tests revealed 29 genome-wide significant genes located in these 4 loci and 8 additional regions. All SNPs combined explained 10% of the variance in lifetime cannabis use.
The most significantly associated gene, CADM2, has previously been associated with substance use and risk-taking phenotypes [2] [3] [4] . We used S-PrediXcan to explore gene expression levels and found 11 unique eGenes. LD-score regression uncovered genetic correlations with smoking, alcohol use and mental health outcomes, including schizophrenia and bipolar disorder. Mendelian randomisation analysis provided evidence for a causal positive influence of schizophrenia risk on lifetime cannabis use.
We performed the largest GWAS of lifetime cannabis use (having ever tried cannabis) to date. We meta-analysed 3 GWASs (International Cannabis Consortium [ICC,] N=35,297; 23andMe, N=22,683; UK-Biobank, N=126,785) with a combined sample size of 184,765 individuals, a five-fold increase compared to the previous largest GWAS for lifetime cannabis use [5] . The meta-analysis resulted in 646 genome-wide significant SNP associations located in 4 independent (linkage disequilibrium [LD] R 2 <0.1, window size 250 kb) regions on chromosomes 3, 8, 11, and 16 (Table 1, Figure 1 , and Supplementary Table S1 ). The most strongly associated marker was an intronic variant of CADM2 on chromosome 3 (rs2875907, p=2.66e -15) . Other hits were located in ZNF704, NCAM1, and RABEP2/ATP2A1 (Figure 2 ). All tested SNPs combined explained 10% (h 2 SNP=0.10, SE=0.01) of the individual differences in lifetime cannabis use; approximately 25% of twin-based heritability estimates [1] . Supplementary Figure S1-3 and Table S2 provide information on results of the individual GWASs.
Gene-based tests of associations in MAGMA [6] identified 29 genes significantly associated with lifetime cannabis use ( Figure 3 , Table 2 , and Supplementary Figure S4-5 ). These were located in the 4 regions identified in the SNP-based analysis and in 8 putatively novel regions. CADM2 and NCAM1, both previously identified in the original ICC meta-analysis [5] , were among the strongest hits. The CADM2 gene (Cell Adhesion Molecule 2) is a synaptic cell adhesion molecule and is part of the immunoglobulin superfamily. Interestingly, CADM2 has previously been identified in GWAS of other behavioural phenotypes, including alcohol consumption [2] , processing speed [7] , and number of offspring and risk-taking behavior [4] . A large-scale phenome-wide scan showed that CADM2 was associated with various personality traits, with the risk variant being associated with e.g. reduced anxiety, neuroticism and conscientiousness, and increased risk-taking [3] . Taken together, these findings suggest that risk variants in CADM2 are associated with a broad profile of a risk-taking, optimistic, and care-free personality [3] . Cannabis use has previously been associated with these personality traits, including high levels of impulsivity and novelty seeking [8, 9] . NCAM1 (Neural Cell Adhesion Molecule 1) also encodes a cell adhesion protein and is member of the immunoglobulin superfamily. The encoded protein is involved in cell-matrix interactions and cell differentiation during development [10] . NCAM1 is located in the NCAM1-TTC12-ANKK1-DRD2 gene cluster, which is related to neurogenesis and dopaminergic neurotransmission. This gene cluster has been associated with smoking, alcohol use, and illicit drug use [11] [12] [13] [14] and has been implicated in psychiatric disorders, such as schizophrenia and mood disorders [15, 16] .
Putatively novel findings in both the SNP-and gene-based test were the ZNF704 region at chromosome 8, about which little is known, and RABEP2/ATP2A1, located in an interesting region on chromosome 16 (see below). Several of the 29 top genes have previously shown an association with schizophrenia (e.g., TUFM, NCAM1), BMI or obesity, alcohol use (e.g. ALDH2), intelligence and cognitive performance, and externalizing and impulsive phenotypes ( Supplementary Table S3 ). At the phenotypic level, associations between cannabis use and psychiatric disorders [17] , use of other substances [8] , personality [18] , and educational attainment [19] are well-established.
S-PrediXcan analysis, aimed at identifying genes with differential expression levels in cannabis users versus non-users [eGenes, 20], largely confirmed SNP-and gene-based findings. S-PrediXcan revealed 51 Bonferroni-corrected significant associations across tissues ( Supplementary   Tables S3 and S4 ) targeting 11 unique eGenes. Five eGenes were also significant in the gene-based tests, whereas 6 were novel. For eGenes identified in multiple tissues, directions of effects were consistent across tissues ( Supplementary Table S4 ). Again, the top finding was CADM2; genetic variants associated with increased liability to use cannabis are predicted to upregulate expression levels of CADM2 in 5 (non-brain) tissues, including whole blood. Of note, although CADM2 is expressed more widely in brain compared with other tissues (Supplementary Figure S6 ), rs2875907 regulates the expression of CADM2 only in non-brain tissues (Supplementary Figure S7 ). Exploration of S-PrediXcan results in UK-Biobank data (https://imlab.shinyapps.io/gene2pheno_ukb_neale/) showed that CADM2 expression is significantly associated with multiple traits, including increased risk-taking and BMI, and reduced feelings of anxiety.
As did the SNP-and gene-based tests, the S-PrediXcan analysis detected a strong signal in a single high-LD region at 16p11.2. Deletions and duplications in this region were previously reported to be associated with autism and schizophrenia [21, 22] , while a common 16p11.2 inversion underlies susceptibility to asthma and obesity [23] . The inversion explains a substantial proportion of variability in expression of the eGenes, including TUFM and SH2B1 [23] . Due to high LD in this region and high levels of co-expression of the eGenes, follow-up studies will be needed to determine which gene(s) are functionally driving the association with cannabis use.
Using our GWAS results and those of other studies, we estimated the genetic correlation of lifetime cannabis use with 25 other traits of interest with LD score regression. Fourteen traits were significantly genetically correlated with lifetime cannabis use, after correction for multiple testing (Figure 4 and Supplementary Table S5 ). Positive genetic correlations were found with substance use phenotypes, including smoking and alcohol use and dependence, as well as with mental health phenotypes, including ADHD and schizophrenia. Furthermore, positive genetic correlations were found with risk-taking behaviour, openness to experience, and educational attainment, as well as a negative correlation with conscientiousness. The broad range of correlations suggests that genetic liability to cannabis use should be viewed in a larger context of personality and mental health traits.
Specifically, the substantial genetic correlations with risk-taking behaviour and openness to experience may indicate liability to start using cannabis is an indication of one's personality.
The relationship between cannabis use and schizophrenia has been subject of intensive research and debate. It has long been established that cannabis use is higher in schizophrenia patients [24, 25] . A substantial body of evidence supports the hypothesis that cannabis use increases the risk for developing schizophrenia [26] , but other hypotheses (i.e. schizophrenia increases use of cannabis, or the association is due to (genetic) pleiotropy) have also been posed. Our results confirm previous findings [27, 28] that genetic risk factors for cannabis use and schizophrenia are positively correlated (rg=0.24, SE=0.03, p<0.01). However, since a genetic correlation does not provide insight in the direction of causation, we performed bi-directional two-sample Mendelian randomisation (MR) analysis [29] to examine whether there is evidence for a causal relationship from cannabis use to schizophrenia and vice versa.
We found no clear evidence for a causal influence of lifetime cannabis use on schizophrenia risk; the Inverse Variance Weighted [IVW] regression odds ratios were 1.01 (95% CIs 0.70-1.45, p=0.97) and 1.03 (95% CIs 0.89-1.19, p=0.70) for the 5e-08 and 1e-05 p-value thresholds for SNP inclusions, respectively. We did find evidence for a causal positive influence of schizophrenia risk on lifetime cannabis use (IVW regression OR=1.16, 95% CIs 1.06-1.27, p<0.01) ( Table 3 ; Supplementary   Tables S6-S9 and Supplementary Figures S8-S9 for details). We performed 4 sensitivity analyses to determine the robustness of this finding; these analyses provided a consistent pattern of effect sizes (with the exception of the MR-Egger analysis) supporting the causal effect from schizophrenia to cannabis use, albeit with weaker statistical evidence (Table 3) . Moreover, the MR-Egger intercept was not significant ( Supplementary Table S9 ), indicating no evidence for pleiotropy [30] . Note that while these methods allow us to infer causality, they do not provide interpretable estimates of the magnitude of the causal effect, as the phenotypes were measured on a logistic scale.
Two previous two-sample MR studies investigated the link between lifetime cannabis use and schizophrenia. The first only tested causal effects from cannabis use to schizophrenia and found evidence for causality [31] , in contrast to our findings. The second study tested bi-directional effects with genetic instruments more similar to ours and found weak evidence for a causal effect of cannabis use to schizophrenia and much stronger evidence for a causal effect in the other direction [32] . Our results reinforce this latter finding, suggesting that genetic risk for schizophrenia causally contributes to an increased liability to use cannabis. A possibility is that individuals at risk for developing schizophrenia experience prodromal symptoms or negative affect that make them more likely to start using cannabis to cope or self-medicate [33] . The lack of evidence of a causal influence of cannabis use on schizophrenia may be due to the lower power of the instrumental variables. The instrumental variable based on schizophrenia SNPs explained 3.38% of variance in liability to schizophrenia. For cannabis use, the genetic instruments explained 0.63% and 0.12% of the variance in cannabis use for SNPs included with p<1e-05 and p<5e-08, respectively.
Our GWAS of lifetime cannabis use, which is the largest to date, revealed significant associations in 12 putatively novel regions. Among these, the most promising candidates for future functional studies are CADM2, NCAM1, the ZNF704 region, and multiple genes located at 16p11.2.
Our findings further indicated a causal influence of schizophrenia on cannabis use and substantial genetic overlap between cannabis use and use of other substances, mental health, and personality traits, such as risk-taking and extraversion.
Online Methods

Samples
Data from 3 sources were obtained: ICC, 23andMe and UK-Biobank (total N=184,765). We used existing GWAS summary statistics from the ICC, based on data from 35,297 individuals of European ancestry from 16 cohorts from Northern America, Europe, and Australia [5] . The overall sample included 55.5% females and the age ranged between 16 
Phenotype and covariates
For all participants, self-report data were available on whether the participant had ever used cannabis during their lifetime: yes (1) versus no (0). Measurement instruments and phrasing of the questions about lifetime cannabis use differed across the samples. For the ICC study this has been described for each cohort in the original paper [5] . As part of their online questionnaire, 23andMe 
Genotyping and imputation
Genotyping was performed on various genotyping platforms and standard quality control checks were performed prior to imputation. Genotype data were imputed using the 1000 Genomes phase 1 release reference set [34] for ICC and 23andMe, and the Haplotype Reference Consortium reference set [35] for the UK-Biobank sample. Information about samples, genotyping, and imputation is summarized in Supplementary Table S10 . After quality control, the ICC sample comprised 35, 297 individuals and 6,643,927SNPs, 23andMe 22,683 individuals and 7,837,888 SNPs, and the UK-Biobank sample 126,785 individuals and 10,827,718 SNPs.
Genome-wide association analyses
We conducted the GWAS in 23andMe and UK-Biobank samples separately. Associations between the binary phenotype and SNPs were tested using a logistic regression model accounting for the effects of sex, age, ancestry, and genotype batch (and age 2 in the UK-Biobank sample). The GWAS for UK-Biobank were performed in PLINK 1.9 [36] and for 23andMe in an internally developed pipeline. We then meta-analysed the GWAS results from ICC, 23andMe, and UK-Biobank. Prior to conducting the meta-analysis, additional quality control of the summary statistics of each study was conducted in EasyQC [37] . Because of varying GWAS methods and sample characteristics (see Supplementary   Table S10 ), slightly different quality control criteria were used for the 3 samples (see Supplementary   Table S11 ). All 3 samples were aligned with the Haplotype Reference Consortium panel using the EasyQC R-package [37] , in order to ensure that RS-numbers and chromosome-basepair positions referred to the exact same variants and to correct for strand effects. Variants were deleted if they had a minor allele frequency diverging more than 0.15 from that in the reference panel.
We applied genomic control to the 3 GWAS files prior to meta-analysis to ensure none of the samples contributed disproportionately to the meta-analysis results [38] . Inflation due to stratification was estimated using LD-score regression; the intercept was used to correct the test statistics (b0= 1.003, SE=0.007 for ICC, b0=1.004, SE=0.006) for 23andMe, b0=1.022, SE=0.007 for UK-Biobank). We then performed a fixed effects meta-analysis based on effect sizes (log odds ratios (OR)) and standard errors in METAL [39] . We applied the conventional p-value threshold of 5e-08 as an indication of genome-wide significance. The meta-analysis was performed on 11,696,151 SNPs that passed quality control. The combined sample size of the meta-analysis was 184,764 individuals, but note that the sample size varies per SNP due to differential missingness across samples.
Regional plots were created using LocusZoom [40] , with varying window size for optimal visualization (see Supplementary Figure S5 ).
Gene-based test of association
Testing associations on the level of protein-coding genes is more biologically meaningful and more powerful (lower multiple testing burden) than testing solely on the level of SNPs. Gene-based analysis was used to test associations for aggregates of variants in protein-coding genes. The analysis was conducted in MAGMA (v 1.6) [6] , which uses the 1000 Genomes reference-panel (phase 3, 2012) to control for LD. SNPs were mapped to genes if they were located in or within 5 kb from the gene, such that 4,760,663 SNPs (41%) could be mapped to at least one of 18,269 protein-coding genes in the reference panel. The significance threshold was set at a Bonferroni corrected p<0.05 (0.05/18,269=2.74e-06).
SNP-based heritability analysis
The proportion of variance in liability to cannabis use that could be explained by the aggregated effect of all SNPs (h 2 SNPs) was estimated using LD-Score Regression analysis [41] . The method is based on the premise that an estimated SNP effect-size includes effects of all SNPs in linkage disequilibrium (LD) with that SNP. A SNP that tags many other SNPs will have a higher probability of tagging a causal genetic variant compared to a SNP that tags few other SNPs. The LD score measures the amount of genetic variation tagged by a SNP within a specific population. Accordingly, assuming a trait with a polygenic architecture, SNPs with a higher LD-score have on average stronger effect sizes than SNPs with lower LD-scores. When regressing the effect size from the association analysis against the LD score for each SNP, the slope of the regression line provides an estimate of the proportion of variance accounted for by all analysed SNPs [41] . For this analysis, we included 1,179,898 SNPs that were present in all cohorts and the HapMap 3 reference panel. Standard LD scores were used as provided by Bulik-Sullivan et al. [41] based on the Hapmap 3 reference panel, restricted to European populations.
Identification of genes with differential expression levels between cannabis users and non-users
We used summary S-PrediXcan to integrate eQTL information with summary statistics from the lifetime cannabis use GWAS meta-analysis to identify eGenes (i.e., genes of which genetically predicted expression levels are associated with cannabis use [20] ). Briefly, S-PrediXcan estimates gene expression weights by training a linear prediction model in samples with both gene expression and SNP genotype data. The weights are then used to predict gene expression from GWAS summary statistics, while incorporating the variance and co-variance of SNPs from an LD reference panel. We used expression weights for 44 tissues from the GTEx Project (V6p) and the DGN whole blood cohort, generated by Gamazon et al. [42] and LD information from the 1000 Genome Project Phase 3 [43] .
These data were processed with beta values and standard errors from the lifetime cannabis use GWAS meta-analysis to estimate the expression-GWAS association statistic. We used a transcriptome-wide significant threshold of p<2.53e-07, which is the Bonferroni corrected threshold when adjusting for all tissues and genes (i.e., 197,680 gene-based tests in the GTEx and DGN reference sets).
We used the GTEXPortal [https://www.gtexportal.org/home/; GTEx Analysis Release V7; 44] to obtain gene expression levels of CADM2 across tissues. We used the same portal to plot a multi-tissue eQTL comparison of the top SNP rs2875907. The multi-tissue eQTL plot shows both the single-tissue eQTL p-value and the multi-tissue posterior probability from METASOFT [45] .
Genetic correlation with use of other substances and mental health phenotypes
We used cross-trait LD-Score regression [46] to estimate the genetic correlation between lifetime cannabis use and 25 other traits using GWAS summary statistics. The genetic covariance is estimated using the slope from the regression of the product of z-scores from 2 GWASs on the LD score. The estimate represents the genetic covariation between the 2 traits based on all polygenic effects captured by SNPs. Summary statistics from well-powered GWASs were available for 25 relevant substance use and mental health traits, including nicotine, alcohol and caffeine use, schizophrenia, depression, bipolar disorder, and loneliness ( Supplementary Table S5 ). To correct for multiple testing we adopted a Bonferroni corrected p-value threshold of significance of 0.002. LD scores were based on the HapMap 3 reference panel, restricted to European populations [47] .
Causal association between cannabis use and schizophrenia: Two-sample Mendelian randomisation
We performed two-sample Mendelian randomisation analyses (MR) [29] to examine whether there is evidence for a causal relationship from cannabis use to schizophrenia or vice versa. All analyses were performed with the R package of database and analytical platform MR-Base [48] .
MR utilizes genetic variants strongly associated with an exposure variable as an 'instrument'
to test for causal effects of the exposure on an outcome variable. This approach minimizes the risk of spurious findings due to confounding or reverse causation present in observational studies, provided that the following assumptions are met: 1) the genetic instrument is predictive of the exposure variable, 2) the genetic instrument is independent of confounders, and 3) the genetic instrument is not directly associated with the outcome variable, other than by its potential causal effect through the exposure (i.e. there is no directional pleiotropy) [49] . Two-sample Mendelian randomisation refers to the application of Mendelian randomisation methods to well-powered summary association results estimated in non-overlapping sets of individuals [29] in order to reduce instrument bias towards the exposure-outcome estimate.
Bi-directional causal effects were tested between lifetime cannabis use and schizophrenia.
We used genetic variants from the cannabis GWAS as well as those from the largest schizophrenia GWAS [50] to serve as instruments (gene-exposure association). For lifetime cannabis use we used 2 genetic instruments; 1) an instrument including all independent genetic variants that were genomewide significantly associated with lifetime cannabis use (p<5e-08; 4 SNPs), and 2) an instrument including independent variants with a more lenient significance threshold (p<1e-05; 37 SNPs). For schizophrenia we used one genetic instrument, including independent genetic variants that were genome-wide significantly associated with schizophrenia (instrument p<5e-08; 109 SNPs). Supplementary Table S6 .
Information on the included SNPs in the genetic instruments is provided in
Genetic variants were pruned (r 2 <0.01) and the remaining genetic variants (or proxies (r 2 ≥0.8) when an instrumental SNP was not available in the other GWAS) were then identified in GWAS summary-level data of the outcome variable (gene-outcome association). Note that because not all exposure SNPs or their proxies are necessarily available also in the outcome dataset and because some SNPs were palindromic not all independent SNPs identified in the exposure dataset have been included in the analyses (see Supplementary Table S6 ).
Evidence for both a gene-exposure and a gene-outcome association suggests a causal effect, provided that the MR assumptions are met. To combine estimates from individual genetic variants we applied inverse-variance weighted (IVW) linear regression [51] . In addition, 4 sensitivity analyses more robust to horizontal pleiotropy were applied, each relying on distinct assumptions regarding instrument validity: Weighted Median [52] , MR-Egger [30] , Simple Mode, and Weighted Mode [53] .
The weighted median approach provides a consistent estimate of the causal effect even when up to 50% of the weight comes from invalid instruments [52] . MR-Egger regression applies Egger's test to MR instruments that consist of multiple genetic variants [30, 54] . MR-Egger provides a consistent estimate of the causal effect, provided that the strength of the genetic instrument (the association between SNPs and exposure) does not correlate with the effect the instrument has on the outcome (i.e. the InSIDE assumption (Instrument Strength Independent of Direct Effect)). This is a weaker assumption than the assumption of no pleiotropy. Finally, the Simple and Weighted Mode methods Inverse Variance Weighted regression analysis (IVW); risk coefficient representing the change in outcome for a one-unit increase in the exposure variable (B); standard error of the B (SE (B)); odds ratios represent the odds of schizophrenia for lifetime cannabis users versus non-users (when cannabis is the exposure) or the odds of lifetime cannabis use for those with a schizophrenia diagnosis versus those without (when schizophrenia is the exposure) (OR); pvalue (p). 
